

## Disclosures

### Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
BMS	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Boehringer Ingelheim Pharmaceuticals, Inc	Other - <i>editorial support through a 3rd party</i>	Modest (< \$5,000)	<a href="#">Other</a>
Medtronic	Research/Research Grants ‡ <i>Not applicable</i>	Modest (< \$5,000)	<a href="#">Arrhythmias and Clinical EP</a>
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Arrhythmias and Clinical EP</a>
Roche Diagnostics	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Acute Coronary Syndromes</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (6)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
American Heart Association † <i>none</i>	Other	None (\$0)	<a href="#">General Cardiology</a>
AstraZeneca HealthCare Foundation	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	<a href="#">General Cardiology</a>
David H Murdock Research Institute	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	<a href="#">Other</a>
NHLBI	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">General Cardiology</a>
NIH	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Other</a>
National Institutes of Health	Data Safety Monitoring Board	None (\$0)	<a href="#">General Cardiology</a>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† *Commercial Funding Source* | ‡ *Trial Name*

## Agreement

### Certified Education Attestation

| Signed on 12/9/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement

| Signed on 12/9/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo

| Signed on 12/9/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement

| Signed on 12/9/2025

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.